Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data from the RUBY Trial

Video

Dr Robert Coleman details data from the RUBY trial investing the role of checkpoint inhibitor dostarlimab in combination with chemotherapy for the treatment of advanced/recurrent endometrial cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

Russ Conroy
September 9th 2025
Article
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
September 9th 2025
Podcast
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
September 9th 2025
Article
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
September 9th 2025
Podcast
The use of 68Ga-Pentixafor compliments fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

CXCR4 Expression in Gynecologic Malignancies Correlates With OS

Roman Fabbricatore
September 9th 2025
Article
More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.

Self-Collection May Help Increase Cervical Cancer Screening Rates

Roman Fabbricatore
September 9th 2025
Article